- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
Information from XVIVO Perfusion´s Nomination Committee – 190115
XVIVO Perfusion AB’s Nomination Committee proposes that the Annual General Meeting to be held on April 25, 2019 re-elects the sitting board members Gösta Johannesson, Camilla Öberg, Yvonne Mårtensson, Alan Raffensperger and Folke Nilsson. Erik von Schenck has relocated to the United States and declined re-election. Gösta Johannesson is proposed to be re-elected as the chairman of the board.
The Nomination Committee proposes election of Dag Andersson as new board member.
Dag Andersson has a long and solid experience from the med tech and life science industry, most recently from the role as CEO for Diaverum AB during 2008-2018, and before that leading positions in Mölnlycke Health Care AB during 1993 – 2007. Dag Andersson has experience as a board member of med tech and life science companies and is currently board member of Nolato AB (publ) and chairman of the board of Diaverum Middle East. Dag Andersson holds an MBA from INSEAD and a BA (Hons) in Business and Commerce from Stockholm School of Economics.
The Nomination Committee’s other proposals will be published in the notice to the Annual General Meeting.
For the 2019 Annual General Meeting, the Nomination Committee members are Henrik Blomquist (Bure Equity), Martin Lewin (Eccenovo AB), Joachim Spetz (Swedbank Robur) and Gösta Johannesson (Chairman of the Board). The members of the Nomination Committee together represent 28 percent of the votes attached to all voting shares in the company. The Nomination Committee has been appointed in accordance with the instruction determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 27, 2018.
The Annual General Meeting will take place on April 25, 2019 in Gothenburg.
XVIVO Perfusion AB (publ)
Nomination Committee Chairman
Tel: 08 – 614 00 20
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Swedish Market Securities Act. The information was submitted for publication, through the agency of the contact person set out above, at 4.00 pm CET on January 15, 2019.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.